Record Details

Maraviroc (Celsentri) in HIV treatment

Farmeconomia

View Archive Info
 
 
Field Value
 
Title Maraviroc (Celsentri) in HIV treatment
 
Creator Sacchi, Viola
 
Subject Pharmacoeconomics; Health economics

 
Description Since 1996, the prognosis of people living with immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) has improved significantly, due to highly active antiretroviral therapies (HAART) based on a combination of 3-4 anti-HIV drugs; the use ofthese drugs can achieve a durable suppression of HIV viraemia, turning HIV infection into a chronic illness. The three first licensed classes of antiretroviral agents are nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs). Until recently, treatment options for individuals developing resistanceto these drugs have been limited, but new drugs in existing classes (second generation NNRTIs and novel PIs) and novel classes of drugs (integrase inhibitors, CCR5 antagonists and fusion inhibitors) have become clinically available.
 
Publisher SEEd Medical Publishers
 
Contributor
 
Date 2008-01-15
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion

 
Format application/pdf
 
Identifier https://journals.edizioniseed.it/index.php/FE/article/view/239
10.7175/fe.v9i4.239
 
Source Farmeconomia. Health economics and therapeutic pathways; Vol 9, No 4 (2008); 219-222
2240-256X
1721-6915
 
Language eng
 
Relation https://journals.edizioniseed.it/index.php/FE/article/view/239/224
 
Coverage


 
Rights Copyright (c) 2008 Farmeconomia. Health economics and therapeutic pathways
http://creativecommons.org/licenses/by-nc/4.0